Description

Ascimib (Asciminib) 40mg 30’ct Tablets by Everest Pharmaceuticals is a medication used primarily for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Asciminib is a tyrosine kinase inhibitor that targets the ABL1 kinase activity of the BCR-ABL1 fusion protein, which is a key driver of CML.

Key Features:

• Composition: Each tablet contains 40 mg of Asciminib.

• Indication: Used for adult patients with Ph+ CML in chronic phase.

• Mechanism of Action: Inhibits the ABL1 kinase activity of the BCR-ABL1 fusion protein, thereby reducing cancer cell proliferation.

• Dosage: Typically taken orally once daily.

• Side Effects: Common side effects may include nausea, vomiting, diarrhea, fatigue, and headache. Serious side effects can include increased risk of infections and bleeding.

Availability:

• Manufacturer: Everest Pharmaceuticals Ltd.

• Packaging: Available in bottles containing tablets.

• Shelf Life: 24 months from the date of manufacture.